Search

Search Constraints

You searched for: Author/Creator Bennett, C Frank

Search Results

1. [O2–17–02]: DISCOVERY AND EARLY CLINICAL DEVELOPMENT OF IONIS‐MAPTRX, THE FIRST TAU‐LOWERING ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH MILD AD. (1st July 2017)

3. Antisense oligonucleotide targeting DMPK in patients with myotonic dystrophy type 1: a multicentre, randomised, dose-escalation, placebo-controlled, phase 1/2a trial. Issue 3 (March 2023)

6. Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Issue 12 (11th May 2019)

7. Downregulation of Survivin contributes to cell-cycle arrest during postnatal cardiac development in a severe spinal muscular atrophy mouse model. (6th December 2017)

8. High-resolution visualization and quantification of nucleic acid–based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS). Issue 1 (4th December 2020)

9. J01 Effects of IONIS-HTTRX (RG6042) in patients with early huntington's disease, results of the first htt-lowering drug trial. (September 2018)